Comparative Pharmacology
Head-to-head clinical analysis: LITFULO versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITFULO versus XELJANZ.
LITFULO vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Litfulo (ritlecitinib) is a Janus kinase (JAK) inhibitor that selectively inhibits JAK3 and to a lesser extent TEC family kinases, thereby modulating the signaling pathways involved in the immune response.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
50 mg orally once daily, with or without food.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 40–60 h), supporting once-daily or twice-daily dosing with steady-state achieved within 10–14 days.
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Primarily excreted unchanged in feces (≈66%) via biliary secretion, with renal excretion accounting for ≈23% as unchanged drug and metabolites; <1% excreted in urine as unchanged parent compound.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category C
Category C
JAK Inhibitor
JAK Inhibitor